Pfizer announced Wednesday that its coronavirus vaccine has shown 100% efficacy in youths ages 12-15 during clinical trials.
The vaccine, developed along with BioNTech, is currently authorized in the U.S. for emergency use for people ages 16 and older.
The companies reported in a Phase 3 trial of 2,260 participants ages 12 to 15 years in the U.S., the vaccine evoked strong antibody responses one month after the second dose, exceeding those demonstrated in people ages 16 to 25 in previous trials, CNN reported.
Researchers logged 18 coronavirus cases among the 1,129 participants who were given a placebo, and none among the 1,131 participants who received the vaccine.
The companies noted the side effects of the vaccine for those ages 12 to 15 were similar to those for 16-to-25-year-olds. The participants will be monitored for two years after their second dose for protection and safety.
Pfizer and BioNTech plan to submit the data, which hasn’t been peer-reviewed, to the Food and Drug Administration for expanded emergency-use authorization of the two-dose vaccine, CNN reported.
Pfizer CEO Albert Bourla said in a statement he hopes to start vaccinating the 12-15 age group before the start of the new school year this fall.
Another study of the vaccine in children ages six months to 11 years began last week, when the first participants ages 5 to 11 were inoculated. The companies seek to start immunizing 2-to-5-year-olds next week and eventually get to participants ages 6 months to 2 years.
Moderna, which also has developed a two-dose vaccine that received FDA emergency clearance, has started testing its vaccine in adolescents and children ages 6 months to 17 years, CNN reported.